Skip to main content
. 2014 Dec 11;3(2):101–112. doi: 10.1007/s40120-014-0023-8

Fig. 1.

Fig. 1

Patient disposition in the randomized, controlled trial and its 12-month open-label extension. AE adverse event, ITT intention to treat, ITT-OC ITT-observed cases